These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 20083823)

  • 41. ACP Journal Club. Review: Neuraminidase inhibitors relieve influenza symptoms and reduce laboratory-confirmed influenza in healthy adults.
    Smieja M
    Ann Intern Med; 2010 Feb; 152(4):JC-211. PubMed ID: 20157123
    [No Abstract]   [Full Text] [Related]  

  • 42. ACP Journal Club: Disclosure of genetic risk for Alzheimer disease did not increase anxiety or depression in asymptomatic adults.
    Pramanik J
    Ann Intern Med; 2009 Nov; 151(10):JC5-9. PubMed ID: 19920267
    [No Abstract]   [Full Text] [Related]  

  • 43. ACP journal club. Regular sunscreen use reduces invasive but not overall melanoma in white adults.
    Lebwohl M
    Ann Intern Med; 2011 May; 154(10):JC5-12. PubMed ID: 21576530
    [No Abstract]   [Full Text] [Related]  

  • 44. ACP Journal Club. A 15-microg dose of unadjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in healthy adults within 21 days.
    Granwehr B
    Ann Intern Med; 2010 Jan; 152(2):JC1-9, JC1-8. PubMed ID: 20083824
    [No Abstract]   [Full Text] [Related]  

  • 45. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
    Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ACP Journal Club. One or two 7.5-microg doses of MF59-adjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in adults within 21 days.
    Granwehr B
    Ann Intern Med; 2010 Jan; 152(2):JC1-8, JC1-9. PubMed ID: 20083823
    [No Abstract]   [Full Text] [Related]  

  • 49. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.
    Durando P; Icardi G; Ansaldi F
    Expert Opin Biol Ther; 2010 Apr; 10(4):639-51. PubMed ID: 20218923
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.